



NDA 215152/S-010

APPROVAL LETTER

Phathom Pharmaceuticals, Inc.
Attention: Nancianne Knipfer, PhD, RAC
Vice President Reg Affairs and Medical Writing
2150 East Lake Cook Road, Suite 800
Buffalo Grove, IL 60089

Dear Dr. Knipfer:

Please refer to your Supplemental New Drug Application (sNDA) dated and received January 6, 2025, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for VOQUEZNA TRIPLE PAK (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets).

This “Changes Being Effected in 30 days” supplemental new drug application provides for the following:

- Addition of (b) (4) as an alternate manufacturer of (b) (4) drug substance vonoprazan fumarate.
- Addition of (b) (4) as an alternate manufacturer of (b) (4) drug substance vonoprazan fumarate.
- Addition of (b) (4)
- Revision of (b) (4) specifications.
- Revision of drug substance analytical procedures to accommodate site differences.
- Revision of container and carton labeling to change the (b) (4) to “Product of U.S.A.”

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELS

Submit final printed carton and container labels that are identical to enclosed carton and container labels and carton and container labels submitted on January 6, 2025, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 215152/S-010.**” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 215152/S-010

Page 3

If you have any questions, contact Utkarsh Desai, Regulatory Business Process Manager, at Utkarsh.Desai@fda.hhs.gov or (301) 796 - 8114.

Sincerely,

{See appended electronic signature page}

David Lewis, Ph.D.
Supervisor
Division of Product Quality Assessment XI
Office of Product Quality Assessment II
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Carton and Container (Blister) Labeling



David
Lewis

Digitally signed by David Lewis

Date: 6/02/2025 07:41:40AM

GUID: 508da72000029f287fa31e664741b577